Literature DB >> 18382760

New drugs approved in 2007.

Erin Sears1.   

Abstract

Year:  2008        PMID： 18382760      PMCID： PMC2277356          DOI： 10.1080/08998280.2008.11928391

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  10 in total

1.  Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.

Authors:  R L Watts; J Jankovic; C Waters; A Rajput; B Boroojerdi; J Rao
Journal:  Neurology       Date:  2007-01-03       Impact factor: 9.910

2.  Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.

Authors:  James L Pool; Roland E Schmieder; Michel Azizi; Jean-Claude Aldigier; Andrzej Januszewicz; Walter Zidek; Yanntong Chiang; Andrew Satlin
Journal:  Am J Hypertens       Date:  2007-01       Impact factor: 2.689

Review 3.  Nebivolol: a third-generation beta-adrenergic blocker.

Authors:  Angie Veverka; Donald S Nuzum; Jamie L Jolly
Journal:  Ann Pharmacother       Date:  2006-07-05       Impact factor: 3.154

4.  The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

Authors:  Peter Hillmen; Neal S Young; Jörg Schubert; Robert A Brodsky; Gerard Socié; Petra Muus; Alexander Röth; Jeffrey Szer; Modupe O Elebute; Ryotaro Nakamura; Paul Browne; Antonio M Risitano; Anita Hill; Hubert Schrezenmeier; Chieh-Lin Fu; Jaroslaw Maciejewski; Scott A Rollins; Christopher F Mojcik; Russell P Rother; Lucio Luzzatto
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

5.  Ambrisentan therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galié; David Badesch; Ronald Oudiz; Gérald Simonneau; Michael D McGoon; Anne M Keogh; Adaani E Frost; Diane Zwicke; Robert Naeije; Shelley Shapiro; Horst Olschewski; Lewis J Rubin
Journal:  J Am Coll Cardiol       Date:  2005-08-02       Impact factor: 24.094

6.  Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study.

Authors:  Peter A LeWitt; Kelly E Lyons; Rajesh Pahwa
Journal:  Neurology       Date:  2007-04-17       Impact factor: 9.910

7.  Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

Authors:  Joseph Biederman; Suma Krishnan; Yuxin Zhang; James J McGough; Robert L Findling
Journal:  Clin Ther       Date:  2007-03       Impact factor: 3.393

8.  Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.

Authors:  Byung-Hee Oh; Jerry Mitchell; James R Herron; Jenny Chung; Mahmudul Khan; Deborah L Keefe
Journal:  J Am Coll Cardiol       Date:  2007-03-20       Impact factor: 24.094

9.  Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.

Authors:  Werner H Poewe; Olivier Rascol; Niall Quinn; Eduardo Tolosa; Wolfgang H Oertel; Emilia Martignoni; Markus Rupp; Babak Boroojerdi
Journal:  Lancet Neurol       Date:  2007-06       Impact factor: 44.182

10.  Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen
Journal:  Blood       Date:  2007-11-30       Impact factor: 22.113
  10 in total
  1 in total

Review 1.  Should Renal Inflammation Be Targeted While Treating Hypertension?

Authors:  Sarika Chaudhari; Grace S Pham; Calvin D Brooks; Viet Q Dinh; Cassandra M Young-Stubbs; Caroline G Shimoura; Keisa W Mathis
Journal:  Front Physiol       Date:  2022-06-13       Impact factor: 4.755
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.